Phost’in Therapeutics announces €2.5m funding from Bpifrance to support regulatory and early clinical development of its First-In-Class N-Glycosylation Inhibitor
Montpellier, France – Sept 2020, 11th
Phost’in Therapeutics (Montpellier, France), a research-driven biopharmaceutical company developing N-glycosylation inhibitors as a First-in-Class immunotherapy for cancer treatment, today announces that it will receive a €2.5 million funding from Bpifrance in addition to its recent Series-A round.
This non-dilutive funding includes €2 million from Bpifrance’s Deeptech program, initiated by the French government, to boost highly innovative and breakthrough projects (…)